Emerging Therapies for Inflammatory Bowel Disease

Keyphrases

• Inflammatory Bowel Disease 100%
• Emerging Therapies 100%
• Clinical Trials 50%
• Etiology 25%
• Toll-like 25%
• Low Dose Rate 25%
• U.S. Food 25%
• Corticosteroids 25%
• Phosphatidylcholine 25%
• Phase III Clinical Trial 25%
• Mode of Action 25%
• Targeted Treatment 25%
• Heterogeneous Groups 25%
• Treatment Modalities 25%
• Patient-reported Outcomes 25%
• Ustekinumab 25%
• JAK Inhibitors 25%
• Vedolizumab 25%
• Surgery Rates 25%
• Action Targets 25%
• Tofacitinib 25%
• Anti-adhesion Agent 25%
• Abrilumab 25%
• Etrolizumab 25%
• Overall Management 25%
• Anti-trafficking 25%

Medicine and Dentistry

• Clinical Trial 100%
• Inflammatory Bowel Disease 100%
• Diseases 66%
• Biological Product 33%
• Patient-Reported Outcome 33%
• Patient with Inflammatory Bowel Disease 33%
• Toll Like Receptor 33%
• Ustekinumab 33%
• Janus Kinase Inhibitor 33%
• Vedolizumab 33%
• Egg Lecithin 33%
• Tofacitinib 33%
• Etrolizumab 33%
• Abrilumab 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Inflammatory Bowel Disease 100%
• Clinical Trial 75%
• Diseases 50%
• Biological Product 25%
• Toll Like Receptor 25%
• Ustekinumab 25%
• Janus Kinase Inhibitor 25%
• Vedolizumab 25%
• Tofacitinib 25%
• Abrilumab 25%
• Etrolizumab 25%
• Egg Lecithin 25%